Press Release
28th November 2005

The 15 billion dollar world of Clinical Research has a major new player in its fastest growing sector, that of phase I clinical trials. Veeda Clinical Research, known as Veeda CR, brings together the highly respected UK CRO Phase 1 CTU, ClinSearch Labs Pvt. Ltd. of Ahmedabad and Triphasic Clinical Trials Laboratories a Plymouth, UK based, GLP accredited laboratory. 

Veeda CR can count many of the world’s top ten Pharmaceutical Companies as clients and sees huge potential in unleashing the synergies of its Indian - European collaboration onto a global market place. Veeda CR’s revenue in India currently stands at 32 crores and is expected to double over the next 12 months.

“Veeda CR represents the ideal bridge between cultures – combining vast experience and expertise in handling the most technically complex trials to the most stringent regulatory standards with the massive technical, data management and volunteer capability of the Indian subcontinent” said Director Mr. Apurva Shah. 

Veeda CR sees its key attribute as its uncompromising commitment to quality and it will use the recognised expertise of its European personnel to help train its research professionals in India. This will be achieved by a two way traffic between continents with research professionals from India undergoing intensive training in the UK and Western project management skills following European research projects into India.
Dr Kiran Marthak, a Director of Veeda CR, is delighted to have joined the Veeda CR at this exciting juncture. Dr Marthak is a pioneer of clinical research activities in India and brings to Veeda CR experience of working with pharmaceutical majors such as Novartis, German Remedies, Pfizer, and Ranbaxy. 

Dr Marthak said “We have managed to combine the best of a top 5 Early Clinical Development Unit in the UK, with all the advantages of a vibrant new unit on the Indian subcontinent, with both Units operating to exactly the same stringent standards set by international regulatory authorities”